LG-631

N/A

Report date: 2023/01/12 15:52:41

Base Information

Drug NameLG-631
Drug Alias NameLG631-CD34LV-P140K MGMTlentiviral transduced MGMT stem-cell therapy (Lentigen/Case Western)LG 631LG631 +[7] 
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of Action6-O-methylguanine-DNA methyltransferase replacementsCell replacements
Targets6-O-methylguanine-DNA methyltransferase
Therapy Area/IndicationsDrug-Related Side Effects and Adverse Reactions
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCase Western Reserve University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOpus BioCase Western Reserve University
Active IndicationsN/A
Inactive IndicationsDrug-Related Side Effects and Adverse Reactions

Other Information

ATC CodeN/A
Related LinksN/A